Long‐term outcomes of second‐line versus later‐line zanubrutinib treatment in patients with relapsed/refractory mantle cell lymphoma: An updated pooled analysis
Cancer Medicine · 2023
DOI: 10.1002/cam4.6473 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Yuqin Song und 21 weiteren Autor:innen. Beteiligte Einrichtung: Peking University Cancer Hospital and Institute, Beijing, China. Hauptthemen laut MEDLINE: Lymphoma, Mantle-Cell, Pyrimidines, Pyrazoles, Piperidines. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
We previously reported results of a pooled analysis of two zanubrutinib studies in relapsed or refractory (R/R) MCL showing better survival outcomes when zanubrutinib is used in second‐line versus later‐line. Here, we present an updated pooled analysis with a longer follow‐up of 35.2 months.
Methods
Data were pooled from two studies—BGB‐3111‐AU‐003 (NCT02343120) and BGB‐3111‐206 (NCT03206970) of zanubrutinib in R/R MCL. The patients were divided into two groups based on the treatment line of zanubrutinib: the second‐line and the later‐line group. The inverse propensity score weighting method was used to balance the baseline covariates between the groups. The primary outcome was overall survival (OS). Secondary outcomes included progression‐free survival (PFS), PFS, and OS rates, objective response rate (ORR), duration of response (DOR), and safety.
Results
Among 112 pooled patients, 41 (36.6%) patients received zanubrutinib as second‐line and 71 (63.4%) patients as later‐line therapy. After weighting, OS was significantly improved in the second‐line versus later‐line group (HR, 0.459 [95% CI: 0.215, 0.98]; p = 0.044) with median OS not estimable in both groups. The PFS was similar between the two groups (HR, 0.78 [95% CI: 0.443, 1.373]; p = 0.389) but with numerically longer median PFS in the second‐line versus later‐line group (27.8 vs. 22.1 months). ORR was numerically higher in the second‐line versus later‐line (88.6% vs. 85.7%), and DOR was similar between the two groups (25.2 vs. 25.1 months). Zanubrutinib showed a similar safety profile in both groups.
Conclusion
Zanubrutinib in second‐line treatment was associated with significantly improved OS compared with later‐line treatment of R/R MCL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Peking University Cancer Hospital and Institute, Beijing, China.
- Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.
- Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Fujian Medical University Union Hospital, Fuzhou, China.
- The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China.
ORCID-Profile: Keshu Zhou, Jianda Hu, Wei Xu, Daobin Zhou, Michael Wang, Stephen Opat, Jun Zhu
Zitieren
APA
Song, Y., Zhou, K., Zou, D., Li, D., Hu, J., Yang, H., Zhang, H., Ji, J., Xu, W., Jin, J., Lv, F., Feng, R., Gao, S., Zhou, D., Tam, C. S., Simpson, D., Wang, M., Phillips, T. J., Opat, S., …, & Zhu, J. (2023). Long‐term outcomes of second‐line versus later‐line zanubrutinib treatment in patients with relapsed/refractory mantle cell lymphoma: An updated pooled analysis. Cancer Medicine. https://doi.org/10.1002/cam4.6473
Vancouver
Song Y, Zhou K, Zou D, Li D, Hu J, Yang H, et al. Long‐term outcomes of second‐line versus later‐line zanubrutinib treatment in patients with relapsed/refractory mantle cell lymphoma: An updated pooled analysis. Cancer Medicine. 2023. doi:10.1002/cam4.6473
BibTeX
@article{Song2023,
author = {Song, Yuqin and Zhou, Keshu and Zou, Dehui and Li, Dengju and Hu, Jianda and Yang, Haiyan and Zhang, Huilai and Ji, Jie and Xu, Wei and Jin, Jie and Lv, Fangfang and Feng, Ru and Gao, Sujun and Zhou, Daobin and Tam, Constantine S and Simpson, David and Wang, Michael and Phillips, Tycel J and Opat, Stephen and Fang, Cheng and Sun, Shaohui and Zhu, Jun},
title = {Long‐term outcomes of second‐line versus later‐line zanubrutinib treatment in patients with relapsed/refractory mantle cell lymphoma: An updated pooled analysis},
journal = {Cancer Medicine},
year = {2023},
doi = {10.1002/cam4.6473}
}
EUVIMED